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Objectives This study sought to assess the prevalence of normal levels of high sensitivity C-reactive protein (hsCRP) at the
very onset of ST-segment elevation myocardial infarction (STEMI).
Background Levels of hsCRP 2 mg/l identify individuals who benefit from lipid lowering and possibly anti-inflammatory
agents, but how many patients develop infarction in spite of hsCRP levels 2 mg/l and thus would be ineligible
for these treatments?
Methods We studied 887 patients with unequivocally documented STEMI as the first manifestation of coronary disease
and 887 matched control subjects from urban areas of Italy, Scotland, and China. Blood samples were obtained
before reperfusion strategies 6 h from symptoms onset in order to limit acute event-related increases.
Results hsCRP values were similar in samples obtained 2 h, 2 to 4 h, and 4 to 6 h from symptoms onset in all ethnic
groups, consistent with the delayed hsCRP elevation after myocardial necrosis and thus indicative of pre-
infarction levels. Median hsCRP values were significantly higher in patients than in control subjects: 2.49 (inter-
quartile range [IQR]: 1.18 to 5.55) mg/l versus 1.32 (IQR: 0.58 to 3.10) mg/l (p  0.0001), which is consistent
with previous findings. However, 41% of patients had hsCRP levels 2 mg/l and conversely, 37% of control sub-
jects had values 2 mg/l.
Conclusions The measurement of hsCRP, with a 2 mg/l cutoff, would not have predicted 41% of unequivocally documented
STEMIs in 3 ethnic groups without evidence of previous coronary disease, thus indicating both its limitations as
an individual prognostic marker and as an indicator of a generalized inflammatory pathogenetic component of
STEMI. New specific prognostic and therapeutic approaches should be found for such a large fraction of patients
at risk. (J Am Coll Cardiol 2011;58:2654–61) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.055Elevated circulating high-sensitivity C-reactive protein (hsCRP)
was found to be predictive of acute coronary syndromes in
secondary (1,2) as well as in primary prevention studies (3),
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December 13/20, 2011:2654–61 Normal hsCRP Levels at STEMI Onsetalthough with variable incremental values above that provided
by established risk factors (RF) (4,5). In addition, healthy
individuals with hsCRP 2 mg/l have been shown to benefit
rom high dose statin therapy, and trials with treatments
pecifically aimed to lower the inflammatory component
uggested by elevated hsCRP are being considered (6). There-
fore, a critical question becomes: What percentage of patients
develops an acute myocardial infarction despite having hsCRP
levels within normal limits?
The prevalence of normal hsCRP levels at the very onset
of acute myocardial infarction indicates the proportion of
patients who would not have been identified as at risk by
baseline, pre-infarction measurements. This percentage
could be underestimated if, in some patients, at admission,
hsCRP was increased because of inflammatory pathogenetic
mechanism of infarction, whereas the effects of necrosis are
unlikely to be detectable in a blood sample taken within 6 h
from the onset of symptoms (7).
We measured circulating levels of hsCRP in carefully
selected patients with unequivocally documented ST-
segment elevation myocardial infarction (STEMI) belong-
ing to different ethnic groups with a 4-fold difference in
coronary artery disease incidence (8): namely, Italians,
Scottish, and Chinese from metropolitan areas, together
with age- and sex-matched control subjects. To minimize
the possible contribution of inflammatory components sec-
ondary to myocardial injury, we included only patients in
whom a blood sample could be obtained within a maximum
of 6 h from the onset of symptoms and prior to coronary
reperfusion strategies. We also excluded patients with pre-
vious evidence of cardiovascular disease to reduce potential
confounding effects of drug therapy and/or lifestyle modi-
fications, as hsCRP levels were not found to have a
predictive value in healthy individuals taking aspirin (9,10).
In addition, we measured interleukin (IL)-6 as an earlier
marker of inflammatory response, which is also a putative
predictor of cardiovascular risk (11). We correlated serum
levels of hsCRP and IL-6 with the time of sampling after
onset of symptoms, with troponin I levels, and with cardio-
vascular RF. Finally, we calculated the average incremental
predictive value for STEMI of hsCRP over that of tradi-
tional RF.
Methods
Study population. In the FAMI (First Acute Myocardial
Infarction) study, participants were recruited from urban
areas of Italy, Scotland, and China (a total of 32 centers
participated) (Online Appendix). These 3 countries were
chosen based on data from the MONICA (Monitoring
Trends and Determinants in Cardiovascular Disease) reg-
istry (8), which showed extreme differences in coronary
artery event rates, with Scotland having 4 times higher
incidence rate of myocardial infarction than China and Italy
did in an intermediate position. All patients, irrespective of
age, who arrived in hospital via the emergency room or yadmitted to the coronary care unit
within 6 h of symptom onset of
STEMI, were screened. Patients
were eligible if they had electrocar-
diographic evidence of STEMI,
no previous history of coronary
artery disease, and reported symp-
tom onset of 6 h. A blood sam-
ple was obtained before any reper-
fusion procedures.
One control subject matched
for age (up to 5 years older or
younger), sex, and environment
(enrolled from the same city) was
recruited for each index case. In-
clusion criteria for control subjects included no previous
diagnosis of coronary disease or history of exertional chest
pain.
A total of 1,206 cases and 984 control subjects were
enrolled between October 2002 and April 2007. Of these,
887 patients and 887 control subjects who met all entry and
matching criteria were finally analyzed in this paper: Figure 1
hows the consort flow diagram, and Table 1 shows the
istribution per country.
isk factor evaluation. Each participating center received
n-site training, either directly by a member of the coordi-
ating center or by the local coordinator, for patient and
ontrol enrollment. A manual explaining all questions in the
ase report forms was distributed with the complete material
or case enrollment. A standardized structured question-
aire was administered, and physical examinations were
ndertaken in the same manner in cases and control
ubjects. Information about demographic factors, socioeco-
omic factors (income, employment, level of education),
ifestyle (physical activity during leisure and work time,
ietary habits), psychosocial factors, and personal and family
istory of cardiovascular disease and traditional RF (smok-
ng, diabetes, dyslipidemia, hypertension) was obtained.
eight, weight, and abdominal circumference were deter-
ined by a standardized protocol (8). Self-reported hyper-
ension and diabetes were used in the analysis of RF. We
onsidered the ratio of apolipoprotein (Apo) B to ApoA1
or dyslipidemia because apolipoprotein concentrations are
ot appreciably affected by fasting status and have been
hown to be superior to any of the traditional cholesterol
atios for estimating the risk of myocardial infarction
12,13). Threshold levels for the tertiles of the ApoB/
poA1 ratio were derived from all control subjects (1).
yslipidemia was calculated from the ApoB/ApoA1 ratio
nd the threshold value was defined as the highest tertile of
ontrol subjects (1.14). We defined current smoking as
ndividuals who currently smoked any tobacco or stopped
moking 1 year prior to the event. Former smokers were
efined as individuals who stopped smoking more than 1
Abbreviations
and Acronyms
Apo  apolipoprotein
CI  confidence interval
hsCRP  high-sensitivity
C-reactive protein
IL  interleukin
IQR  interquartile range
OR  odds ratio
RF  risk factor(s)
STEMI  ST-segment
elevation acute myocardial
infarctionear earlier.
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Normal hsCRP Levels at STEMI Onset December 13/20, 2011:2654–61The case report forms were both paper and electronic.
We developed a real-time, online framework for the collec-
tion, control, and verification of case report forms and study
management forms, as well as for real-time study progress
monitoring and quality control procedures.
Data on smoking were missing in 0.4% of participants,
hypertension in 0.6%, diabetes in 0.5%, and abdominal
circumference in 0.6%.
Nonfasting blood samples (50 ml) were drawn from each
patient before treatment. After separation, microaliquots of
serum, sodium-citrate plasma, heparin plasma, and whole
blood were frozen immediately at –80°C. Fasting blood
samples were drawn from each control subject and processed
Figure 1 Consort Flow Diagram of Enrollment
Enrollment Numbers and Age and Sex Distributifor the Overall Population and for Individual EthnTable 1 Enrollment Numbers a Age and Sfor the Overall Population and for In
Patients (n  887
Men
Overall (n  887)
Men  681
Women  206
59 11.72 6
Italy (n  320)
Men  255
Women  65
60 11.14 6
Scotland (n  210)
Men  159
Women  51
59 11.73 6
China (n  357)
Men  267
Women  90
58 11.86 7Values are age, mean  SD. In the 3 ethnic groups, men were about 9 yearssimilarly. All samples were shipped by courier in dry ice to
the core laboratory in Milan, Italy, where they were stored
at –80°C (Polar 530V AHSI-Angelantoni freezer, Milan,
Italy). Serum samples from all countries were analyzed at
the Università Vita-Salute San Raffaele Core laboratory for
ApoB, ApoA1, hsCRP, troponin I, and IL-6. Turbidime-
tric assays were used to measure ApoA1 and ApoB concen-
trations in serum samples (Cobas Mira Plus/Horiba ABX,
Kyoto, Japan). High and low concentrations as control
subjects (Horiba ABX) were analyzed in every run, and a
pool control serum that had previously been tested in the
core laboratory was measured for all analytes. IL-6 was
measured using an enzyme-linked immunoadsorbent assay
roupsistribution
ual Ethnic Groups
Control Subjects (n  887)
n Men Women
.90 59 11.51 68 10.55
.52 59 11.05 68 10.94
.91 59 11.70 66 12.12
.84 57 11.80 67 9.27onic Gex D
divid
)
Wome
8 11
9 11
8 11
0 11older than women.
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December 13/20, 2011:2654–61 Normal hsCRP Levels at STEMI Onsetkit (R&D Systems, Minneapolis, Minnesota), and a pool of
control serum was tested in all plates to determine interassay
precision (detection limit: 0.16 to 50.0 pg/ml, and interassay
variability, defined by a coefficient of variation of 11.3%).
Immunochemical luminescent assays were used to measure
hsCRP (detection limit: 0.10 to 150.0 mg/l, and interassay
variability, defined by a coefficient of variation of 10.2%)
and troponin I concentration in serum with Immulite 2000
(Medical Systems SpA, Genoa, Italy). High and low control
concentrations were analyzed for each analyte. Every cali-
bration kit (collected about every 1 or 2 weeks) and a pool
control serum that had previously been tested in the core
laboratory was measured for all analytes every run. Several
aliquots for each case and control were saved for future
analysis.
The FAMI Study was approved by appropriate regulatory
and ethics committees in all participating centers in all 3
countries. All participants provided informed consent before
taking part in the study.
Statistical analysis. Comparisons between cases and control
subjects were performed by paired t tests or Wilcoxon test and
cNemar test as appropriate. A conditional logistic regression
or matched pairs was run. Univariate models for each single
F and a multivariate analysis were run. Interactions of each
ingle RF with ethnic groups were tested. In order to investi-
ate the risk of STEMI associated with multiple RF, a model
ncluding the number of classical RF (diabetes mellitus, hyper-
ension, dyslipidemia, smoking) was run and the predictive
alue of hsCRP 2 mg/l for STEMI was tested, including
sCRP and its interaction with the number of RF. Estimates
f odds ratios and accompanying 95% confidence intervals are
resented for each RF.
Statistical analysis and graphics were produced with
TATA (version 9.2, StataCorp, College Station, Texas),
PSS (version 13, IBM SPSS, Chicago, Illinois), and
raphPad Prism (version 5, GraphPad Software, La Jolla,
alifornia).
esults
total of 887 patients with acute myocardial infarction
ccurring as their first manifestation of coronary artery
Clinical Characteristics for the Overall Population and Separated bTable 2 Clinical Characteristics for the Overall Population and
Overall Italian
Symptoms time, min 180 (110–270) 165 (100
Troponin I, ng/ml 0.62 (0.20–3.26) 0.74 (0.20
Peak CPK, U/l 1,606 (770–3,037) 1,355 (650
Therapy
Aspirin 142 (16) 67 (21)
Beta-blocker 62 (7) 29 (9)
ACE inhibitor/ARB 89 (10) 48 (15)
Statin 44 (5) 19 (6)
Other lipid-lowering agents 6 (0.67) 3 (1)Values are median (interquartile range) or n (%). p value refers to overall comparison among Italians, Sc
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CPK  creatine phosphokisease and 887 matched control subjects were included in
he study (Fig. 1). Overall, 76% of patients in the total
opulation were men, and their mean age at presentation
as 9 years lower than that of women (68  11.9 years vs.
9  11.7 years) across all 3 ethnic groups (Table 1). There
as a very low percentage of patients on cardiovascular
rugs, as we eliminated those with a previous history of
ardiovascular disease (Table 2). The diagnosis of infarction
as documented unequivocally in all by the presence of
T-segment elevation on presentation and by the subse-
uent peak creatine phosphokinase: median 1,606 (inter-
uartile range [IQR]: 770 to 3,037) U/l. In addition, 795
89.6%) patients underwent emergency coronary reperfusion
herapy. Overall, 34.4% of STEMI patients had 1 or more
pisodes of angina in the 48 h preceding admission prior to
he incident that brought them to hospital admission.
In these patients with a definite STEMI, the interval
etween symptom onset and blood sampling was short
nough not to have increased appreciably pre-existing
sCRP levels, as troponin I in the admission blood sample
as 0.2 ng/ml in 52% of patients and was only slightly
levated in the remaining patients: median 2.09 (IQR: 0.32
o 14.03) ng/ml. Indeed, there was no difference in hsCRP
evels in patients sampled 2, 2 to 4, or 4 to 6 h from the
nset of symptoms. Moreover, hsCRP levels were similar in
atients with troponin I 0.2 and 0.2 ng/ml. Thus, these
sCRP values are likely to closely reflect those preceding the
cute event.
Although these patients had an unequivocally docu-
ented acute STEMI, 40.9% had admission hsCRP values
ower than the cutoff value of 2 mg/l; conversely, 37.0% of
ontrol subjects had values  2 mg/l, with distribution of
alues similar across the 3 ethnic groups.
Median hsCRP levels in the admission blood sample in
he whole study group were significantly higher than those
f control subjects: median 2.49 (IQR: 1.18 to 5.55) mg/l
ersus median 1.32 (IQR: 0.58 to 3.10) mg/l, respectively
p  0.0001), but with a very large overlap (Fig. 1). Indeed,
7.0% of STEMI patients had hsCRP values lower than the
edian value for control subjects and, conversely, 31.1% of
ontrol subjects had values higher than the median value for
ntryrated by Country
Scottish Chinese p Value
140 (93–228) 210 (130–300) 0.0001
) 0.39 (0.20–1.38) 0.73 (0.20–4.1) 0.0001
) 1,745 (945–3,465) 1,760 (708–3,059) 0.005
42 (20) 32 (9)
25 (12) 11 (3)
23 (11) 18 (5)
23 (11) 11 (3)
1 (0.4) 3 (0.8)y CouSepa
s
–261)
–4.41
–2,616ottish, and Chinese.
inase; IQR  interquartile range.
e
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ity, and overall accuracy for identifying the presence of
STEMI with a 2 mg/l cutoff were 66%, 64%, and 65%,
respectively.
There were no significant differences in hsCRP levels
between patients with (34.4% of the cases) and without
(65.6%) episodes of angina in the 48 h preceding admission:
median 2.65 (IQR: 1.13 to 5.82) versus median 2.39 (IQR:
1.16 to 5.37), respectively, p  NS.
Interleukin 6 levels were also significantly higher in
patients than in control subjects, with a large overlap:
median 5.08 (IQR: 2.88 to 9.89) pg/ml versus median 1.38
(IQR: 0.71 to 2.67) pg/ml (p 0.0001), respectively, and in
ach ethnic group, about 20% of patients had values above
0 pg/ml (Fig. 2). There was no correlation between hsCRP
nd IL-6 levels. Also, levels of IL-6 were not statistically
ifferent in patients sampled2 h, 2 to 4 h, or 4 to 6 h from
nset of symptoms, but levels of IL-6 were slightly elevated
n patients who had troponin I 0.2 pg/ml: median 5.7
Figure 2 hs-CRP and IL-6 Levels
Scatter plot distribution of patients and control subjects of high-sensitivity C-reacti
(B). Scatter plot of patients and control subjects for interleukin (IL)-6 admission le
the y axis for IL-6. For both markers in all graphs, patients versus control subjects(IQR: 3.3 to 10.8) pg/ml versus median 4.4 (IQR: 2.5 to 8)
pg/ml (p  0.0025).
Both Scottish patients and their control subjects had
slightly higher admission values of hsCRP than the Italians
and Chinese did (p  0.001), but the absolute difference
between patients and control subjects was similar in all 3
ethnic groups. The levels of IL-6 were not different across
the 3 groups.
Overall, there was a significant association between
hsCRP levels 2 mg/l and first myocardial infarction for
the entire population and for all 3 ethnic groups. In the
overall population adjusted for age, sex, smoking, dyslipi-
demia, diabetes, hypertension, and body mass index, the
odds ratio was 2.24 (95% confidence interval [CI]: 1.42 to
3.28) for hsCRP (Fig. 3), which is comparable to that
reported in previous primary prevention studies (14) and an
odds ratio (OR) of 5.89 (95% CI: 4.37 to 7.96) for IL-6.
The high predictive value of IL-6 levels suggests that, in
spite of the early time of sampling after the onset of
tein (hsCRP) admission levels for the total population (A) and for each country
r the total population (C) and for each country (D). Note the scale change on
0.0001. IQR  interquartile range.ve pro
vels fo
: p 
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December 13/20, 2011:2654–61 Normal hsCRP Levels at STEMI Onsetsymptoms, IL-6, but not hsCRP levels, reflected an acute
myocardial infarction–related component, as indicated by
the higher IL-6 values observed in patients with elevated
troponin I.
The overall prevalence of the 4 major modifiable cardio-
vascular RF (smoking habit, dyslipidemia, hypertension,
and diabetes) was significantly higher in patients than in
control subjects (p  0.0001). Each of them was found to
have a significant predictive value for STEMI in the whole
study group after adjustment for age, sex, and for the
remaining RF (Fig. 3). There were no significant interac-
tions with the ethnic groups in the multivariate analysis.
The risk of STEMI associated with multiple RF was: 1 RF:
OR: 1.21 (95% CI: 0.79 to 1.87); 2 RFs: OR: 2.64 (95% CI:
1.68 to 4.15); 3 RFs: OR: 6.41 (95% CI: 2.64 to 15.55); 4
RFs: OR: 10.12 (95% CI: 2.88 to 32.66). However, the
majority of patients presenting with their first acute myo-
cardial infarction had only 1 or 2 of the major RF, whereas
the number of patients with 3 or 4 RF was rather small,
which is consistent with previous reports (15). A similar
trend was observed in all 3 ethnic groups.
The presence of hsCRP 2 mg/l had an incremental
predictive value for STEMI in patients with 1 or more RF
with an OR of 2.12 (95% CI: 1.63 to 2.75) (p  0.0001)
(Fig. 4). The incremental predictive value of hsCRP did not
Figure 3 Prevalence of Traditional RF and Elevated hsCRP
Prevalence of traditional risk factors (RF) and elevated high-sensitivity C-reactive p
the RF with ST-segment elevation myocardial infarction (STEMI) for the overall pop
hypertension, and body mass index. Cutoff for CRP is 2 mg/l.differ when only patients with troponin I 0.2 ng/ml wereconsidered: OR: 2.09 (95% CI: 1.42- to 2.92). There were
no significant differences in the number of cardiovascular
RF among patients with hsCRP 2 mg/l and those with
hsCRP 2 mg/l (Table 3).
Discussion
Our findings indicate that in over 40% of 887 patients
admitted within 6 h from symptoms onset for an unequiv-
ocally documented STEMI, before emergency reperfusion
strategies were performed in 89.6% of the cases, hsCRP
serum levels were below 2 mg/l. The percentage of low
baseline levels might have been even larger if, in some
patients, the baseline hsCRP value became elevated above
baseline just before the sampling time because of the acute
infarction process. This possibility appears unlikely for
myocardial necrosis because of the early sampling, but it
cannot be excluded for potential inflammatory triggers of
infarction.
At any rate, a substantial percentage of patients appears to
develop acute STEMI in spite of baseline levels of hsCRP
2 mg/l and, hence, would not be eligible for preventive
strategies now under consideration (16).
The median values and interquartile ranges of hsCRP in
our patients and control subjects were similar to those
(hsCRP) for the overall population and for each ethnic group and association of
. Odds ratios are adjusted for age, sex, smoking, dyslipidemia, diabetes,rotein
ulationreported in previous preventive studies (14), which however
2660 Cristell et al. JACC Vol. 58, No. 25, 2011
Normal hsCRP Levels at STEMI Onset December 13/20, 2011:2654–61were only focused on median values and did not give
appropriate consideration to the wide dispersion of val-
ues, largely overlapping with those of control subjects,
and to its practical implications.
Indeed a very wide dispersion of values of hsCRP was
reported in the control subjects of PROVE IT–TIMI 22
(Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy–Thrombolysis In Myocardial Infarction 22) study (14)
and found to be unrelated to the low-density lipoprotein
cholesterol levels. Our findings also demonstrated that
patients with unequivocally documented very acute STEMI
exhibit a very wide dispersion of values and a broad overlap
with control subjects (Fig. 2). The wide dispersion of hsCRP
values was observed in spite of the selection of a phenotypically
homogeneous group by restricting the inclusion criteria to
patients with STEMI within 6 h from onset of symptoms
occurring as their very first manifestation of coronary disease,
very few of whom were on cardiovascular drugs. Previous
reports from our group indicated that hsCRP was higher in
patients in whom infarction was preceded by “severe unstable
angina” (17), but the findings were not confirmed in the
present report based on a much larger number of patients, in
Figure 4 Increased Risk Associated With Elevated hsCRP
Odds ratios for STEMI associated with exposure to multiple RF (smoking, dyslipide
and incremental odds ratio associated with the presence of hsCRP 2 mg/l. Abbr
Distribution of RF Among Control Subjects and Patients Divided onTable 3 Distribution of RF Among Control Subjects and Patient
n 0 RF
Control subjects 887 254 (28.5)
Patients with hsCRP 2 mg/l 363 45 (12,2)
Patients with hsCRP 2 mg/l 524 48 (9.2)Values are n (%).
hsCRP  high-sensitivity C-reactive protein; RF  risk factor(s).any of the 3 ethnic groups, possibly because of less stringent
definition of “unstable angina.”
The intriguing observation of markedly elevated levels of
IL-6 above 10 pg/ml in about 20% of patients in each ethnic
group (Fig. 2) and the lack of correlation with hsCRP levels
suggested the investigation of the inflammatory components
of STEMI at the 2 extreme ends of the spectrum in
matched patients with either markedly elevated or very low
IL-6 levels. The biological and genetic characterization of
these 2 extreme groups are currently in progress using some
of the multiple samples stored in the central biological bank,
but conclusive results are not yet available. Such differences
are not related to commonly considered variables, because
these 2 extreme groups had similar incidence of pre-
infarction angina, similar estimated infarct size, similar
levels of hsCRP, and similar RF profile. Among those
patients with hsCRP 2 mg/l, more than 80% had 2
traditional RF, a proportion not significantly different from
that observed in patients with hsCRP 2 mg/l (Table 3).
Current work includes the study of a set of 48 single
nucleotide polymorphisms potentially involved in multiple
biological pathways.
iabetes, and hypertension) for each group of 0, 1, 2, 3, and 4 RF
ns as in Figure 3.
Basis of hsCRP <2 or >2 mg/lided on the Basis of hsCRP <2 or >2 mg/l
1 RF 2 RF 3 RF 4 RF
381 (43.0) 204 (23.0) 45 (5.1) 3 (0.4)
135 (37.3) 139 (38.3) 40 (11.1) 4 (1.1)
176 (33.5) 215 (41.1) 76 (14.5) 9 (1.7)mia, d
eviatiothes Div
3C
W
d
c
T
(
d
t
o
f
p
m
p
2661JACC Vol. 58, No. 25, 2011 Cristell et al.
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finding of hsCRP levels 2 mg/l in 41% of the cases in all
ethnic groups considered.
onclusions
e found that 41% of patients in 3 different ethnic groups
evelop an acute STEMI as the very first manifestation of
oronary disease despite having hsCRP levels below 2 mg/l.
his observation indicates that the current reductionist
“one size fits all”) approach based on statistically significant
ifferences in median values might have limitations when
he dispersion of values about the median is very wide and
verlaps with control subjects (18,19). In such a large
raction of patients, it appears mandatory to search for new
athophysiological mechanisms in order to identify specific
arkers of risk and novel therapeutic targets for effective
reventive strategies.
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APPENDIX
For a list of centers participating in the FAMI study, as well as the
FAMI Investigators’ acknowledgments, please see the online version of
this paper.
